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↑ What is "already known" in this topic: {#box1}
========================================

Rheumatoid arthritis is one of the most common inflammatory diseases. Sex hormones can apply some immunological changes, so it seems they may affect the rheumatoid arthritis disease activity

→ What this article adds: {#box2}
=========================

Hormones in oral contraceptive pills can reduce rheumatoid arthritis disease activity and severity among women in reproductive age.

Introduction {#s1}
============

Rheumatoid arthritis (RA) is one of the most common autoimmune diseases of connective tissue and is considered as a rheumatic disease. Women, especially in the third to the fifth decades of life, are affected by RA 3 times more than men.  RA prevalence is about 0.8% to 1% ([@R1], [@R2]). According to the World Health Organization report in 2009, RA prevalence in Iran is about 0.34%, which is similar to other Asian countries and lower than Western countries ([@R3], [@R4]). Eventually, rheumatoid arthritis can influence different aspects of life, especially physical and psychological dimensions, which can impair the quality of patient's life ([@R5], [@R6]). Pregnancy, especially unwanted pregnancy, in these women is an important concern. Because affected women have disabilities in various degrees, they receive health care and family planning services less than they should ([@R7]). On the other hand, pregnancy is more complicated in these women because of limitations and problems associated with rheumatoid arthritis. Thus, one of the most important issues in women, especially those with chronic medical diseases such as rheumatoid arthritis, is contraception‏. Some studies have shown that oral contraceptive pills (OCPs) have a positive effect on rheumatoid arthritis disease activity ([@R8]).

It seems that all family planning methods, even intrauterine devices, can be used in patients with RA who are not receiving immunosuppressive therapy. However, still oral contraceptive pills are the best and most effective choice that may have a positive effect on RA development ([@R9]). As hormones can apply some immunological changes and rheumatoid arthritis is an autoimmune disease, it is likely that hormones included in oral contraceptive pills can reduce the disease activity and severity ([@R10], [@R11]).

Despite years of study on the effects of sex hormones and oral contraceptives pills on RA, much controversy still exists about their positive effects, and thus the effects of oral contraceptives cannot be conclusively confirmed ([@R12], [@R13]). Chen et al. (2014) indicated that OCPs use cannot prevent RA onset but can protect the patient's disease severity progression ([@R4]). However, Doran et al. (2004) believed OCPs exposure, especially in earlier years of life, can play a prominent role in protection against RA development ([@R7]). Thus, it is recommended that more studies be conducted on this subject, especially in communities of different races ([@R12], [@R13]). As no study has been performed in this field in Iran, in this study, we examined the effect of oral contraceptive pills on rheumatoid arthritis activity in Iranian women of reproductive age.

Methods {#s2}
=======

Patients {#s2-0-1}
--------

This randomized clinical control trial was performed on 100 women with rheumatoid arthritis (50 women in the intervention and 50 in the control groups graded according to the American Rheumatism Association criteria) who referred to the rheumatology clinics of Shariati and Rasool Akram hospitals in Tehran, Iran, in 2011. Consecutive sampling method was used and women who met the inclusion criteria were allocated to 2 study groups using random block size of 2 (50 women in each group). Women with any mental and physical problems (except rheumatoid arthritis), pregnancy, or women with any OCPs taking contraindications were not included in the study.

Intervention and assessment {#s2-0-2}
---------------------------

Informed consent was obtained from all participants and they were provided with consultation for family planning (The registry code: IRCT 138904224364N1; ethical code: 250/ 6441). Those women who wanted to choose OCPs as contraception method and had no contraindication for the hormones were included in the intervention group. Women in the control group chose non-hormonal methods for contraception. As these women had to take OCPs for contraception, the control group could not receive placebo instead of OCPs due to risk of pregnancy. Before any intervention, women in the 2 study groups were assessed for disease activity using DAS-28 international tools by an expert rheumatologist. DAS-28 consists of 3 parts: ([@R1]) clinical, including the number of swollen joints and tenderness joints; ([@R2]) laboratory test, including erythrocyte sedimentation rate; and ([@R3]) general health, or patient\'s global assessment of disease activity during the last 7 days on visual analogue scale of 0-100mm scaled ruler. The general scope of the score in this tool is between 0 to10. Scores lower than 3.2 are considered as mild disease activity, the scores between 3.2 and 5.1 as average disease activity, and those higher than 5.1 as severe disease activity ([@R14]). Then, low dose OCPs (Iran Hormone Co. contains 0.03 milligrams ethinyl estradiol and 0.15 milligrams levonorgestrel) were given to the intervention group. Women started taking OCPs during the first 5 days of their menstrual cycles and continued for 4 weeks. Then, OCPs were discontinued for 1 week but administered again in the following 4 weeks. During these 9 weeks, women were followed weekly to ensure that they were taking OCPs correctly or to detect any probable side effects. Women in the 2 groups were treated with the same drug regimen for their rheumatologic‏ complications. The control group did not receive any hormonal intervention. The same rheumatologist repeated the disease activity assessment for both groups after 9 weeks.

Statistical analysis {#s2-0-3}
--------------------

Data were analyzed using SPSS software 14 and were reported as mean±SD or frequency and percentage. For quantitative data, Kolmogorov--Smirnov test was used before statistical analysis to ensure data normality. Then, data were compared with student t test and paired t test. Chi-square test was used to analyze qualitative data and significance level was set at p\<0.05.

Results {#s3}
=======

A total of 100 women participated in the study (50 in the intervention and 50 in the control groups). The mean±SD age of women in the OCPs and control groups were 38.48±7.47 and 40.58±8.19 years, respectively (p=0.77). The BMI of women in OCPs group was 28.12±4.97 kg/m^2^ and it was 26.88±4.73 kg/m^2^ in the control group (p = 0.22).‏ Women in OCPs and control groups were affected by RA for 9.00±6.94 and 8.72±7.05 years, respectively (p=0.19), and they received RA drugs for 8.72±7.05 and 7.90±5.58 years, respectively (p=0.80). [Table 1](#T1){ref-type="table"} demonstrates some characteristics of the participants in the study.

###### Characteristics of OCPs and control groups

  --------------------- ----------------------- --------------------- ------------------------ ------
  Variable                                      OCPs Group (n = 50)   Control Group (n = 50)   p
  Educational statues   Under high school       32(64%)               26(52%)                  0.22
                        High school & diploma   15(30%)               20(40%)                  
                        Academic education      3(6%)                 4(8%                     
  Occupation status     Household               48(96%                43(86%)                  0.81
                        Occupied                2(4%                  7(14%)                   
  Family income         Low^1^                  12(24%)               15(30%)                  0.32
                        Moderate^2^             38(76%)               35(70%)                  
                        High^3^                 \-                    \-                       
  Parity                0                       9(18%)                10(20%)                  0.33
                        1-3                     28(56%)               21(42%)                  
                        ≥4                      13(26%)               19(38%)                  
  Live child            0                       18(36%)               10(20%)                  0.16
                        1-3                     21(42%)               29(58%)                  
                        ≥4                      11(22%)               11(32%)                  
  Exercise^4^           Yes                     4(8%)                 6(12%)                   0.50
                        No                      46(92%)               44(88%)                  
  --------------------- ----------------------- --------------------- ------------------------ ------

According to [Table 2](#T2){ref-type="table"}, the 2 study groups did not have any significant differences in DAS28 parameters or the total score before the intervention. After intervention, swollen joints score (p=0.02), joint tenderness score (p=0.02), general health (p\<0.001), and DAS28 total score (p=0.04) in OCPs were significantly lower than the control group, but ESR did not show any significant differences between the 2 groups.

###### Comparison of DAS28 clinical and laboratory parameters between the study groups before and after intervention

  ------------------------ ---------------------- ------------ ------------------- ---------------------- ------------- ------- ------
  Parameter                Before                 After        ES^\*^                                                           
  OCPs group (M±SD)        Control group (M±SD)   p            OCPs group (M±SD)   Control group (M±SD)   p                     
  Swollen joints score     2.1(0.42)              1.4(0.22)    0.10                1.3(0.25)              2.2(0.31)     0.02    2.19
  Joint tenderness score   3.02(0.52)             2.4(0.31)    0.06                2.2(0.41)              3.7(0.48)     0.02    2.12
  ESR                      25.9(2.9)              19.8(2.09)   0.09                22.6(2.30)             22.08(2.20)   0.87    1.11
  General health           5.9(0.27)              5.4(0.29)    0.23                3.7(0.25)              5\. 9(0.28)   0.001   4.82
  Total score of DAS28     3.94(1.13)             3.58(1.07)   0.10                3.35(1.00)             3.78(1.23)    0.04    0.33
  ------------------------ ---------------------- ------------ ------------------- ---------------------- ------------- ------- ------

\*Effect size

According to severity of disease activity (DA), the comparison of mean±SD of DA severity in each group before and after the study revealed a significant DA reduction (3.94±1.13 vs. 3.35±1.00, respectively) in OCPs group (p=0.001) but not in the controls (3.58±1.07 vs. 3.79±1.22 respectively). As demonstrated in [Table 3](#T3){ref-type="table"}, there were no significant differences between the 2 study groups before the intervention; however, after the intervention, DA severity was significantly different between the 2 groups, as most women in the OCPs group (52%) had mild DA severity and those in the control group (58%) had moderate severity (p=0.04).

###### Comparison and frequency distribution of disease activity severity in the study groups before and after intervention

  --------------------------------- ---------------- --------- ------------- ---------------- --------- ------
  Disease activity classification   Before           After                                              

  OCPs group\                       Control group\   p         OCPs group\   Control group\   p         
  N (%)                             N (%)                      N (%)         N (%)                      

  Mild (DAS\<3.2)                   10(20%)          20(40%)                 26(52%)          15(30%)   

  Moderate (3.2≤DAS≤5.1)            34(68%)          26(52%)                 21(42%)          29(58%)   

  Sever (DAS\>5.1)                  6(12%)           4(8%)     0.10          3(6%)            6(12%)    0.04
  --------------------------------- ---------------- --------- ------------- ---------------- --------- ------

Neither of the 50 women who participated in the OCPs group complained of OCP side effects.

Discussion {#s4}
==========

The main goal of this study was to examine the effect of oral contraceptive pills (OCPs), which contain both estrogen and progesterone, on rheumatoid arthritis disease activity. The results revealed that OCPs can improve and reduce the severity of rheumatoid arthritis (RA) activity in women of reproductive age with RA according to the 28-joint DAS. This can be due to the belief that sex hormones may contribute to the rheumatoid arthritis (RA) activity because of their role in the immune system response, as estrogens can enhance humoral system reactions and androgens and progesterone can suppress the immune system ([@R15]). Some believe that hormonal imbalance occurs in women with RA, and thus production or action of estrogens and androgens will be impaired. These changes can regulate RA onset, severity, and progression ([@R16], [@R17]). Nevertheless, the effect of OCPs on RA is not clear and there are many controversies surrounding the issue ([@R18]) because people respond differently to hormones. Although there are several studies about the role of OCPs in RA development, it is not clear whether OCPs can prevent or postpone RA. Recent studies have not shown any significant relationship between hormone replacement therapy (HRT) and RA ([@R19]). Similarly, Pikwer et al. (2009) indicated that there is not any association between having a history of OCPs and rheumatoid arthritis risk reduction ([@R20]). On the other hand, Jorgensen et al. (1996) found that using OCPs can protect against rheumatoid arthritis ([@R21]). Moreover, Cutolo et al. (2010) showed that androgens and steroid alternatives can adjust inflammatory status of joint tissue because sex hormones balance is a fundamental regulator of immune system and inflammatory reactions ([@R11], [@R12]). A study showed OCPs can reduce mild RA development in women who used OCPs for more than 5 years without any significant effect on long- term outcome of RA ([@R22]).

RA is likely to improve during pregnancy; thus, estrogen therapy or using OCPs can be suggested for younger women with RA, as they can benefit from non-contraceptive effects of OCPs ([@R23]). Also, a preventive effect against RA is proposed for oral contraceptive pills, and this effect is exerted by estrogens as a modulator in the immune system. Sapir-Koren and Livshits (2016) believe that steroid and androgenic hormones can be applied as a noteworthy therapeutic modulator for rheumatoid arthritis ([@R24]). Oral contraceptive pills can improve RA even before the RA symptoms emerge. Camacho et al. (2011) suggest that using OCPs before or around the symptom onset may propose long-lasting advantages ([@R25]).

One of our limitations in the present study was that as our participants used OCPs as a contraceptive method, we could not use placebo due to the risk of unwanted pregnancy. Besides, we did not assess the long- term effect of OCPs in women with RA due to time limitation.

Conclusion {#s5}
==========

Family planning is one of the most important concerns for women of reproductive age. Oral contraceptive pills are not only good contraceptive methods but also, according to our results, these pills can improve RA activity in affected women. Thus, it seems that these women can benefit from OCPs more than others.

The results of the present study support those of previous studies that found positive effects of OCPs on RA severity and activity.

Acknowledgement {#s6}
===============

This paper was extracted from an MSc thesis in midwifery and was financially supported by Tehran University of Medical Sciences, Tehran, Iran.

Conflict of Interests {#s7}
=====================

The authors declare that they have no competing interests.
